Teleflex Reports Study Results of ARROWg+ard® Technology Effectiveness in Reducing Catheter Infections and Costs in Low Risk Population

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Teleflex Reports Study Results of ARROWg+ard® Technology Effectiveness in Reducing Catheter Infections and Costs in Low Risk Population

Brean Capital Raises Price Target on Teleflex (TFX) to $145 Following 2Q Results

July 31, 2015 7:24 AM EDT

Brean Capital reiterated a Buy rating on Teleflex (NYSE: TFX), and raised the price target to $145.00 (from $135.00), following 2Q results. Teleflex reported 2Q15 adjusted EPS of $1.42, in line with consensus. Revenue was in line with expectations at $452.1 million, versus consensus estimate of $453 million.

Analyst Jason Wittes commented, "Teleflex reported 2Q15 adjusted EPS of $1.42, in line with consensus of $1.42 and $0.02 above our $1.40 estimate,... More